ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Pyroptosis-Related Signature Predicts Overall Survival and Immunotherapy Responses in Lung Adenocarcinoma

Zhu, Kaibin; Yan, An; Zhou, Fucheng; Zhao, Su; Ning, Jinfeng; Yao, Lei; Shang, Desi; Chen, Lantao*哈尔滨医科大学
Frontiers in Genetics2022-6-20DOI: 10.3389/fgene.2022.891301
3被引9阅读
引用收藏
分享

摘要

Background: Lung adenocarcinoma (LUAD) is a highly malignant cancer with a bleak prognosis. Pyroptosis is crucial in LUAD. The present study investigated the prognostic value of a pyroptosis-related signature in LUAD.Methods: LUAD's genomic data were downloaded from TCGA and GEO databases. K-means clustering was used to classify the data based on pyroptosis-related genes (PRGs). The features of tumor microenvironment were compared between the two subtypes. Differentially expressed genes (DEGs) were identified between the two subtypes, and functional enrichment and module analysis were carried out. LASSO Cox regression was used to build a prognostic model. Its prognostic value was assessed.Results: In LUAD, genetic and transcriptional changes in PRGs were found. A total of 30 PRGs were found to be differentially expressed in LUAD tissues. Based on PRGs, LUAD patients were divided into two subgroups. Subtype 1 has a higher overall survival rate than subtype 2. The tumor microenvironment characteristics of the two subtypes differed significantly. Compared to subtype 1, subtype 2 had strong immunological infiltration. Between the two groups, 719 DEGs were discovered. WGCNA used these DEGs to build a co-expression network. The network modules were analyzed. A prognostic model based on seven genes was developed, including FOSL1, KRT6A, GPR133, TMPRSS2, PRDM16, SFTPB, and SFTA3. The developed model was linked to overall survival and response to immunotherapy in patients with LUAD.Conclusion: In LUAD, a pyroptosis-related signature was developed to predict overall survival and treatment responses to immunotherapy.

学科与关键词

关键词
glycosyltransferaselung adenocarcinomaprognosisgene signatureimmunotherapy
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2022-06-20
卷期
第 13 卷
页码
891301
DOI
10.3389/fgene.2022.891301
期刊等级
3区
成果收录
SCIE
资助标注
Research Funds for the Provincial Universities [2020-KYYWF-1469]; Scientific Research Subject of Heilongjiang Health Committee [2019061]

作者

  • Z

    Zhu, Kaibin (第一作者)

    harbin med univ

  • Y

    Yan, An

    harbin med univ

查看全部 8 位作者收起作者
  • Z

    Zhou, Fucheng

    harbin med univ

  • Z

    Zhao, Su

    harbin med univ

  • N

    Ning, Jinfeng

    harbin med univ

  • Y

    Yao, Lei

    harbin med univ

  • S

    Shang, Desi

    harbin med univ

  • C

    Chen, Lantao (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417